Prestige Biopharma to Participate in CPHI Milano... Expanding Global Partnerships

Prestige Biopharma announced on October 7 that it will participate in "CPHI Milano 2026," a global pharmaceutical and biotechnology industry exhibition held in Milan, Italy, with the aim of expanding its global partnerships.

CPHI Milano 2026 Prestige Biopharma Booth / Photo by Prestige Biopharma

During the event, which runs from October 6 to 8, the company will hold discussions with global pharmaceutical and biotech firms at its booth located within the comprehensive pharmaceutical zone. Prestige Biopharma plans to explore business cooperation opportunities for its major biosimilars, antibody drug pipelines, next-generation platforms, and diagnostic technologies. The company will discuss potential collaborations with global leaders in each field, leveraging its diversified portfolio spanning therapeutic development, drug delivery, and diagnostics.

At this year’s event, Prestige Biopharma aims to secure new commercialization partners in untapped markets, based on the product approval achievements of its trastuzumab biosimilar, Tuznue, in Europe, Brazil, and the Caribbean region.

In the biosimilar sector, Prestige Biopharma is seeking global partners for joint development and commercialization of new candidates—including those under development targeting market entry synchronized with the expiry of original drug patents.

For its antibody drug business, the company will seek to expand joint development and licensing discussions for Ulenistamab (PBP1510) and PBP1710. PBP1510, a first-in-class antibody candidate targeting pancreatic cancer, is preparing for subsequent clinical trials based on Phase 1 clinical data, while PBP1710 is under development for fibrotic diseases and solid tumors.

The company will also introduce its PisaJusa (SC) drug delivery platform and TASA™, an early diagnostic platform for pancreatic cancer capable of detecting the overexpressed factor PAUF in blood. PAUF is known to be overexpressed in more than 80% of pancreatic cancer patients and plays a key role in cancer progression and metastasis.

So-yeon Park, Chairwoman of Prestige Biopharma, stated, "With Tuznue securing regulatory approvals not only in Europe but also in Brazil and the Caribbean region, we will continue to expand our global business by acquiring new partners in untapped regions. At CPHI, we plan to identify practical partnership opportunities and forge stronger global collaborations in biosimilar joint development, antibody drugs, drug delivery platforms, and the TASA™ diagnostic technology."

This content was produced with the assistance of AI translation services.